Rare Multi-Organ Immune Reaction from Cancer Drug Combination

While immune checkpoint inhibitors (ICIs), like sintilimab, have revolutionized the treatment of various cancers by unleashing the body's immune system against tumor cells, their combination with other immunomodulators is an area of active research. Sintilimab specifically targets the PD-1 receptor, a checkpoint that normally prevents immune cells from attacking healthy tissues, thereby allowing T-cells to attack cancer. Thymosin alpha-1 (Tα1) is another immunomodulatory peptide known to enhance T-cell function and maturation. Although these agents might offer synergistic anti-tumor effects, the precise safety profile of combining them remains largely unexplored, and this case report highlights the potential for severe, multisystemic immune-related adverse events (irAEs) when these powerful immunomodulators are used concurrently.

Following the administration of the combined sintilimab and thymosin alpha-1 therapy, the patient rapidly developed severe multisystemic immune-related adverse events (irAEs). The initial symptoms included a high fever and a widespread rash, indicating a systemic inflammatory response. This quickly progressed to more critical conditions, notably interstitial pulmonary edema, which signifies fluid accumulation and inflammation within the lungs, severely impairing respiratory function. The severity of the immune overactivation was profound, leading to a rapid deterioration in the patient's overall health. > The most critical finding was the swift progression to multiple organ failure, demonstrating a severe and uncontrolled immune response affecting several vital systems simultaneously. This severe adverse reaction necessitated immediate and intensive medical intervention, highlighting the potent and potentially dangerous synergistic effects of combining these two immunomodulatory agents, which resulted in an overwhelming immune activation rather than a targeted anti-tumor effect.